GLP-1 Medications and Type 2 Diabetes: Beyond Weight Loss

When most people hear "semaglutide," they think about the remarkable weight loss results plastered across headlines. But for the more than 37 million Americans living with type 2 diabetes — and the 96 million with prediabetes — GLP-1 receptor agonists offer something even more profound: a chance to fundamentally reverse the course of the disease. Here's what the clinical evidence actually shows.

What Is a GLP-1 Receptor Agonist?

GLP-1 stands for glucagon-like peptide-1, a hormone naturally released by your intestines in response to food. It signals the pancreas to release insulin when blood sugar rises, tells the liver to stop dumping glucose into the bloodstream, and slows gastric emptying so glucose from food enters the blood more gradually. It also acts on the brain to reduce appetite and increase satiety.

In people with type 2 diabetes, this natural GLP-1 response is blunted. GLP-1 receptor agonists — including semaglutide (Ozempic/Wegovy), liraglutide (Victoza/Saxenda), and tirzepatide (Mounjaro/Zepbound) — are engineered molecules that mimic and amplify this response, lasting far longer in the body than the native hormone.

The result is not a band-aid on symptoms. These medications address multiple underlying drivers of type 2 diabetes simultaneously: insulin secretion, glucagon suppression, gastric emptying, hepatic glucose output, and caloric intake. No other drug class targets so many pathways at once.

The A1C Data: SUSTAIN Trials

The SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) trial program is one of the most comprehensive bodies of evidence ever assembled for a diabetes drug. Across eight large randomized controlled trials involving thousands of patients with type 2 diabetes, once-weekly semaglutide demonstrated consistent, clinically meaningful A1C reductions.

Key A1C Findings from SUSTAIN

• SUSTAIN 1 (monotherapy): Semaglutide 0.5 mg reduced A1C by 1.45 percentage points; 1.0 mg reduced it by 1.55 points versus 0.02 points for placebo.
• SUSTAIN 2 (vs. sitagliptin): Semaglutide reduced A1C by up to 1.6 points versus 0.5 points for sitagliptin — more than three times the reduction of a leading oral diabetes drug.
• SUSTAIN 3 (vs. exenatide ER): Semaglutide 1.0 mg reduced A1C by 1.5 points versus 0.9 points for exenatide — demonstrating superiority over an existing GLP-1 agent.
• SUSTAIN 7 (vs. dulaglutide): Semaglutide again outperformed another GLP-1, with 1.0 mg achieving a 1.9 point A1C reduction.

To put those numbers in perspective: most oral diabetes medications achieve A1C reductions of 0.5–1.0%. Getting to target (below 7.0% for most adults) from a starting A1C of 8.5–9.0% is genuinely possible with semaglutide in ways it simply is not with older agents.

Tirzepatide's SURPASS trials pushed the boundary further. SURPASS-2 showed tirzepatide 15 mg reduced A1C by an average of 2.34 percentage points — the largest A1C reduction ever documented in a phase 3 trial for any diabetes medication.

What Does This Mean for Prediabetes?

Prediabetes — defined as an A1C between 5.7% and 6.4%, or fasting glucose between 100 and 125 mg/dL — affects roughly 1 in 3 American adults. Most will never receive any pharmacological intervention, despite the fact that 15–30% will progress to full type 2 diabetes within five years.

The STEP 1 trial (primarily a weight loss study) found that participants on semaglutide 2.4 mg who had prediabetes at baseline reverted to normoglycemia at a dramatically higher rate than those on placebo. After 68 weeks, 84.1% of participants in the semaglutide group who had prediabetes at baseline had normal blood sugar levels, compared with 47.8% in the placebo group. For the right patient, early intervention with a GLP-1 may prevent diabetes from ever developing.

Cardiovascular Outcomes: SUSTAIN-6 and Beyond

Perhaps the most revolutionary aspect of GLP-1 therapy isn't what it does to blood sugar — it's what it does to the heart.

The SUSTAIN-6 cardiovascular outcomes trial enrolled 3,297 patients with type 2 diabetes and high cardiovascular risk. Patients were followed for up to two years. The primary endpoint was a composite of cardiovascular death, non-fatal myocardial infarction (heart attack), and non-fatal stroke — together called MACE (major adverse cardiovascular events).

Semaglutide reduced the risk of MACE by 26% compared to placebo (6.6% vs. 8.9%; HR 0.74; p<0.001 for noninferiority, p=0.02 for superiority). Stroke risk alone was reduced by 39%. These are significant, clinically meaningful reductions in life-altering events — not just lab numbers.

The LEADER trial of liraglutide and the REWIND trial of dulaglutide showed similar cardioprotective findings, establishing the cardiovascular benefit as a class effect rather than specific to one molecule. The mechanism is thought to involve reduced arterial inflammation, improved endothelial function, modest blood pressure reduction, and the indirect benefits of weight loss on cardiac workload.

Tirzepatide's SURPASS-CVOT results, published in 2025, confirmed similar cardiovascular risk reduction in high-risk patients with type 2 diabetes, cementing dual GIP/GLP-1 agonism as cardioprotective as well.

Kidney Protection: An Underappreciated Benefit

Diabetic kidney disease (diabetic nephropathy) is the leading cause of end-stage renal disease in the United States. Approximately 40% of people with type 2 diabetes will develop some degree of kidney disease. For decades, RAAS inhibitors (ACE inhibitors and ARBs) were the only medications with proven kidney-protective effects in this population.

That changed with GLP-1 data. The FLOW trial — a dedicated renal outcomes trial of semaglutide in patients with type 2 diabetes and chronic kidney disease — was stopped early by its independent data monitoring committee because the benefit was so clear. Semaglutide reduced the composite kidney disease endpoint (sustained decrease in eGFR of ≥50%, kidney failure, or death from kidney or cardiovascular causes) by 24% compared to placebo. Kidney disease progression was reduced by 22%.

The FDA has since approved semaglutide for reduction of kidney disease progression in adults with type 2 diabetes and CKD — a landmark indication that goes well beyond glucose control.

Combining GLP-1 With SGLT2 Inhibitors

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) are another class of diabetes medications that work by causing the kidneys to excrete excess glucose in the urine. They've also demonstrated significant cardiovascular and kidney benefits. The obvious clinical question: what happens when you combine them with GLP-1 agonists?

Complementary Mechanisms, Additive Benefits

GLP-1s and SGLT2 inhibitors work through entirely different pathways — GLP-1 through insulin/glucagon regulation and appetite suppression; SGLT2 through glucosuria, osmotic diuresis, and reduced cardiac preload. Clinical evidence suggests their benefits are additive:

• An additional 0.5–0.7% A1C reduction when combined vs. either drug alone
• Additive weight loss effects (SGLT2 inhibitors cause modest 2–3 kg weight loss independently)
• Potentially additive cardiovascular and renal protection through distinct mechanisms
• SGLT2-mediated blood pressure reduction complements GLP-1's modest antihypertensive effect

Major diabetes guidelines, including those from the American Diabetes Association and the European Association for the Study of Diabetes, now recommend considering both drug classes for patients with established cardiovascular disease, heart failure, or chronic kidney disease — not only for glucose control, but for organ protection independent of A1C.

Who Should Consider GLP-1 Therapy for Diabetes?

GLP-1 receptor agonists are appropriate for a broad range of patients with type 2 diabetes, but they're particularly compelling in the following situations:

• A1C not at goal on metformin alone: GLP-1s are among the preferred add-on agents per current guidelines, particularly when weight loss is desired
• Established cardiovascular disease: SUSTAIN-6 and LEADER data support GLP-1 use as first intensification in this population
• Chronic kidney disease: The FLOW trial data supports semaglutide specifically
• Significant obesity (BMI ≥30): Weight loss of 10–20% of body weight amplifies glycemic benefit
• Prediabetes at high risk of progression: Off-label use supported by STEP data showing normalization of blood sugar
• Insulin-dependent patients seeking to reduce insulin dose: GLP-1s often allow significant insulin reduction, lowering hypoglycemia risk

GLP-1 agonists are generally not appropriate for people with type 1 diabetes (different mechanism of disease), a personal or family history of medullary thyroid carcinoma, or multiple endocrine neoplasia syndrome type 2 (MEN-2).

Side Effects and Managing Tolerability

The most common side effects of GLP-1 medications are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These occur most frequently during dose escalation and typically improve significantly after the first 4–8 weeks. Starting at the lowest dose and titrating slowly is the single most effective strategy for improving tolerability.

Pancreatitis, while included in prescribing information, has not been confirmed as causally increased in large outcome trials. Gallbladder disease (including gallstones) is more common with rapid weight loss and appears modestly elevated. The retinopathy signal observed in SUSTAIN-6 (an increase in diabetic retinopathy complications with rapid A1C reduction) underscores the importance of ophthalmology monitoring when starting GLP-1 therapy in patients with known retinopathy.